COMP <GO>
RDGT vs CVS // ENTERPRISE SCALE & MARKET CAP
Ridgetech Inc. (NASDAQ) VS. CVS Health Corporation (NYSE) • 15-METRIC TALLY: RDGT 1
— CVS 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: CVS
LAST: $0.80 (-3.32%) • MKT CAP: $3.0M
market-cap
$3.0M
LAST: $90.25 (-0.09%) • MKT CAP: $115.53B
market-cap
$115.53B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RDGT VS. CVS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RDGT | CVS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 3.60% | 45.00% | -41.40 | CVS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 2.60% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 25.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 6.76% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -1.40% | 1.20% | -2.60 | CVS | /operating-margins <GO> |
| Net Profit Margin | -0.90% | 0.40% | -1.30 | CVS | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | 7.80% | +2.40 | RDGT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.94% | -2.94 | CVS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.31 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 7/9 | -6.00 | CVS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 47.8 | -0.80 | CVS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.88 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 60.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $3.0M | $115.53B | -$115.53B | CVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RDGT REV | CVS REV | RDGT GROSS % | CVS GROSS % | RDGT FCF | CVS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $132.2M | $402.07B | 3.6% | 45.0% | -$1.4M | $7.81B |
| FY 2024 | $120.0M | $372.81B | 3.2% | 44.7% | $1.1M | $6.33B |
| FY 2023 | $124.0M | $357.78B | — | — | -$3.2M | -$2.67B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RDGT // BETA —
CVS // BETA 0.88